CAMBRIDGE, Mass. – November 15, 2021 – Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Tara Place, MBA, as Vice President, Human Resources and Organizational Effectiveness. Ms. Place brings more than 20 years of experience as a global human resources leader with broad experience and proven expertise in building cultures that attract, retain and develop world class talent. At Catamaran, she will be responsible for all aspects of human resources, building organizational strategies and talent management, and will be a key contributor to the company’s plans for growth.
“Tara is a great addition to our leadership team, and her strategic perspective and extensive HR background will be instrumental in supporting Catamaran’s growth,” said Alvin Shih, MD, Chief Executive Officer of Catamaran Bio. “With the rapid progress we have made on our early pipeline of CAR-NK cell therapies, our company is poised for rapid expansion, and I look forward to working with Tara to continue to build our company’s leadership position in the cell therapy space.”
“It is an extremely exciting time to join Catamaran, and I am thrilled to have the opportunity to contribute to the company’s evolution and growth,” said Ms. Place. “Catamaran has a groundbreaking technology platform and differentiated pipeline programs, and I am delighted to be part of building a high-performing team to bring these new and innovative CAR-NK cell therapies to cancer patients.”
Prior to joining Catamaran, Ms. Place led human resources at Chiasma, Inc., where she oversaw all organizational development and HR initiatives, including talent acquisition, leadership development, and employee retention strategies, as the company transitioned to a commercial biotech organization. During her tenure with Vertex Pharmaceuticals and Biogen, she held leadership roles in many aspects of human resources, including talent acquisition, learning and development, employee engagement, and diversity and inclusion. Tara holds a BA in Psychology from Boston University and an MBA from Simmons Graduate School of Management.
About Catamaran Bio
Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND™ platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program. For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBioon Twitter.
Catamaran contact:
Mark Boshar, Chief Operating Officer
617-620-9709
mark@catamaranbio.com
Media Contact:
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com